Central China Normal Univ. HPK1 compound 2 t

Central China Normal Univ. HPK1 compound 2 t: sourced facts only. name: "This work highlights 2 t as a potent and selective HPK1 inhibitor and a promising lead compound for cancer immunotherapy." [PMID:40902512]; target: "This work highlights 2 t as a potent and selective HPK1 inhibitor and a promising lead compound for cancer immunotherapy." [PMID:40902512]; developer: "State Key Laboratory of Green Pesticide, Central China Normal University, Wuhan, 430079, PR China." [PMID:40902512]; stage: "It also enhanced T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, achieving a tumor growth inhibition (TGI) rate of 76 %, compared to 70 % with anti-mPD-1 monotherapy, 2 t also exhibited moderate bioavailability (F = 31.8 %) in mice and showed synergistic effects with anti-mPD-1 antibodies in the MC38 mouse model, although no significant differences were observed." [PMID:40902512]